Rofecoxib

Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .

Product Specifications

CAS Number

[162011-90-7]

Product Name Alternative

MK 966

UNSPSC

12352005

Hazard Statement

H302

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Rofecoxib.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C1OCC(C2=CC=C(S(=O)(C)=O)C=C2)=C1C3=CC=CC=C3

Molecular Formula

C17H14O4S

Molecular Weight

314.36

Precautions

H302

References & Citations

[1]Rofecoxib, et al. Rofecoxib [Vioxx, MK-0966; 4- (4'-methylsulfonylphenyl) -3-phenyl-2- (5H) -furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290 (2) :551-60.|[2]Liu NN, et al. Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression. Clin Exp Ophthalmol. 2015 Jul;43 (5) :458-65.|[3]Stoppoloni D, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer. 2010 Feb 2;9:27.